Heron Therapeutics Inc.

1.84
0.00 (0.00%)
At close: Apr 17, 2025, 3:59 PM
1.89
2.72%
Pre-market: Apr 21, 2025, 09:12 AM EDT
0.00%
Bid 1.8
Market Cap 280.29M
Revenue (ttm) 153.74M
Net Income (ttm) -13.58M
EPS (ttm) -0.09
PE Ratio (ttm) -20.44
Forward PE 36.8
Analyst Buy
Ask 1.89
Volume 784,084
Avg. Volume (20D) 1,700,383
Open 1.81
Previous Close 1.84
Day's Range 1.79 - 1.86
52-Week Range 1.04 - 3.93
Beta 1.40

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 1987
Employees 122
Stock Exchange NASDAQ
Ticker Symbol HRTX
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 226.09% from the latest price.

Stock Forecasts
1 month ago
+20.49%
Heron Therapeutics shares are trading higher follo... Unlock content with Pro Subscription
1 month ago
+19.88%
Heron Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.